CytomX Therapeutics Inc (CTMX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】CytomX Therapeutics Inc (CTMX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8121)・商品コード:DATA904C8121
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:73
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
CytomX Therapeutics Inc (CytomX) is a clinical-stage biopharmaceutical company which develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s leading product candidates include CX-072, CX-2009, BMS-986249, CX-2029, CX-188, probody drug conjugate, and T-cell bispecific. CX-072, currently under Phase 1/2 clinical trial, is a PD-L1 targeting Probody therapeutic for the treatment of cancer. CX-2009, currently under Phase 1/2 trial, is a CD166-directed PDC for the treatment of cancer. BMS-986249, under Phase 1/2 clinical trial, is a CTLA-4-directed Probody therapeutic intended for the treatment of solid cancers. CX-2029, under Phase1/2 clinical trial, is a PDC directed against CD71 intended for the treatment of B-cell lymphoma. CX-188, under preclinical studies, is a PD-1-targeting Probody therapeutic. The company partners with other pharmaceutical companies to develop its novel therapeutics. CytomX is headquartered in South San Francisco, California, the US.

CytomX Therapeutics Inc (CTMX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CytomX Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
CytomX Therapeutics Raises USD70 Million in Series D Venture Financing 13
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 15
CytomX Therapeutics Raises US$1.2 Million In Series B-1 Financing 16
Cytomx Therapeutics Raises Additional US$11 Million In Series B Financing 17
Partnerships 19
Amgen and CytomX Therapeutics Enter into Co-Development Agreement 19
Applied BioMath to Enter into Agreement with CytomX Therapeutics 20
CytomX Therapeutics Enters into Agreement with University of Texas M. D. Anderson Cancer Center 21
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 22
Licensing Agreements 24
AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 24
AbbVie Enters into Licensing Agreement with CytomX Therapeutics 26
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 28
Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 29
Equity Offering 31
CytomX Therapeutics Raises USD125 Million in Public Offering of Shares 31
CytomX Therapeutics Files Registration Statement for Public Offering of Shares 33
CytomX Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 34
CytomX Therapeutics Raises USD92 Million in IPO 35
CytomX Therapeutics Raises USD3.5 Million in Private Placement of Preferred Stock 37
CytomX Therapeutics Raises USD1.4 Million in Private Placement of Preferred Stock 38
CytomX Therapeutics Raises USD0.5 Million in Private Placement of Preferred Stock 39
CytomX Therapeutics Raises USD8.4 Million in Private Placement of Preferred Stock 40
CytomX Therapeutics Inc – Key Competitors 41
CytomX Therapeutics Inc – Key Employees 42
CytomX Therapeutics Inc – Locations And Subsidiaries 43
Head Office 43
Recent Developments 44
Financial Announcements 44
Aug 08, 2018: CytomX Therapeutics announces second quarter 2018 financial results 44
May 09, 2018: CytomX Therapeutics Announces First Quarter 2018 Financial Results 46
Mar 07, 2018: CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update 48
Nov 07, 2017: CytomX Announces Third Quarter 2017 Financial Results and Operational Progress 50
Aug 07, 2017: CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call 53
May 05, 2017: CytomX Announces First Quarter 2017 Financial Results 55
Mar 02, 2017: CytomX Announces Full-Year 2016 Financial Results 56
Corporate Communications 57
Dec 18, 2017: CytomX Therapeutics Added to NASDAQ Biotechnology Index 57
Oct 24, 2017: CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors 58
May 15, 2017: CytomX Announces Management Team Changes 59
Mar 30, 2017: CytomX Therapeutics Appoints Marion McCourt to Board of Directors 60
Product News 61
09/08/2017: CytomX Announces Poster Presentation On CX-072 At European Society for Medical Oncology Annual Meeting 61
09/08/2017: CytomX Therapeutics To Present Poster On CX-2009 At European Society for Medical Oncology Annual Meeting 62
06/29/2017: CytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate 63
06/28/2017: CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial 64
06/04/2018: CytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probody Platform and CX-072 at 2018 ASCO Annual Meeting 65
06/01/2018: CytomX Announces Conference Call and Webcast to Review PROCLAIM-072 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 67
05/17/2017: CytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting 68
05/16/2018: CytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting 69
02/02/2017: CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial 71
Product Approvals 72
May 22, 2018: CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CytomX Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CytomX Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CytomX Therapeutics Raises USD70 Million in Series D Venture Financing 13
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 15
CytomX Therapeutics Raises US$1.2 Million In Series B-1 Financing 16
Cytomx Therapeutics Raises Additional US$11 Million In Series B Financing 17
Amgen and CytomX Therapeutics Enter into Co-Development Agreement 19
Applied BioMath to Enter into Agreement with CytomX Therapeutics 20
CytomX Therapeutics Enters into Agreement with University of Texas M. D. Anderson Cancer Center 21
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 22
AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 24
AbbVie Enters into Licensing Agreement with CytomX Therapeutics 26
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 28
Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 29
CytomX Therapeutics Raises USD125 Million in Public Offering of Shares 31
CytomX Therapeutics Files Registration Statement for Public Offering of Shares 33
CytomX Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 34
CytomX Therapeutics Raises USD92 Million in IPO 35
CytomX Therapeutics Raises USD3.5 Million in Private Placement of Preferred Stock 37
CytomX Therapeutics Raises USD1.4 Million in Private Placement of Preferred Stock 38
CytomX Therapeutics Raises USD0.5 Million in Private Placement of Preferred Stock 39
CytomX Therapeutics Raises USD8.4 Million in Private Placement of Preferred Stock 40
CytomX Therapeutics Inc, Key Competitors 41
CytomX Therapeutics Inc, Key Employees 42

List of Figures
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CytomX Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[CytomX Therapeutics Inc (CTMX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8121)販売に関する免責事項を必ずご確認ください。
★調査レポート[CytomX Therapeutics Inc (CTMX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆